KCRI’s Post

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation

💗 Johnson & Johnson MedTech’s Impella ECP shows safety and efficacy in IDE study The IDE study is the first clinical trial completed on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture. Impella ECP technology is developed by Abiomed, a company of Johnson & Johnson MedTech. The IDE study established the safety and efficacy of Impella ECP in high-risk percutaneous coronary intervention (PCI), with a major adverse cardiac and cerebrovascular events (MACCE) rate of 6.3%. Read more online: https://lnkd.in/e9_MiTst 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

US HCPs: Dr. Jeff Beecher showcases a standout Science Based Aspiration Thrombectomy (SBAT) case utilizing BMX81, Velocity, and RED 62 in the M1. The case highlights the power of optimal catheter sizing for effective recanalization. "And some people say we need catheters larger than a 72." Excellent work, Dr. Beecher! Rx only. For risk info: peninc.info/risk Clinical results may vary

Xuzhou Medical University (NCT05509530) - ORR: 86% (18/21), CR+: 62% (13/21) - MRD negative rate: 81% (17/21) - 2.0 × 10^6 CAR T cells/kg dose: ORR 82% (11/12), CR+ 75% (9/12) What are the effective regimens for multiple myeloma? 1. BCMA ADC + GPRC5D ADC❓ 2. BCMA×GPRC5D ADC❓ 3. BCMA TCE + GPRC5D TCE; Teclistamab+Talquetamab resulted in somewhat disappointing CR rates. 4. BCMA×GPRC5D TCE; JNJ-5322 5. BCMA CAR-T + GPRC5D CAR-T❓ 6. BCMA×GPRC5D CAR-T; BMS 7. CAR-T + TCE or ADC❓ https://lnkd.in/grtFpsUE

Great insights from this distinguished panel!

🔍 3 key benefits in addressing 𝐬𝐭𝐞𝐫𝐧𝐚𝐥 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬? 💡 🔹 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐑𝐞𝐝 𝐅𝐥𝐚𝐠𝐬 𝐄𝐚𝐫𝐥𝐲: The MUST score allows you to categorise patients by risk, ensuring those at higher risk receive the attention they need. 🔹 𝐓𝐚𝐢𝐥𝐨𝐫𝐞𝐝 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: With adaptable treatment options for all risk levels, you can proactively choose the best approach for each patient. This helps to achieve better results, even in the most complex cases. 🔹 𝐁𝐚𝐥𝐚𝐧𝐜𝐞𝐝 𝐂𝐚𝐫𝐞: Implement strategies that improve patient outcomes while keeping costs in check. This balance helps maintain high standards of care without financial strain. 🎥 Watch our expert-led webinair and explore these benefits, available below 👇 #CardiacSurgery #PatientCare #SurgicalInnovation #ERAS #SternalClosure 𝘍𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘰𝘯 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘱𝘭𝘦𝘢𝘴𝘦 𝘳𝘦𝘢𝘤𝘩 𝘰𝘶𝘵 𝘵𝘰 𝘺𝘰𝘶𝘳 𝘭𝘰𝘤𝘢𝘭 𝘴𝘢𝘭𝘦𝘴 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘷𝘦.

Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera Mapping and Ablation System for sustained VT, a serious heart condition. Medtronic Cardiovascular Portfolio’s Cardiac Ablation Solutions business vice-president and chief medical officer Khaldoun Tarakji, MD MPH said: “We look forward to learning more about how the Sphere-9 Catheter, which offers physicians the ability to map and ablate with the option of choosing PF or RF, together with a large lattice-tip for managing the large target areas for ablation that typically present with VT, can be a useful tool for this challenging arrythmia" Click here for the full article - https://lnkd.in/dxXNPa-w #medicaldevice #medtech #cardiovascular #ablation

We're excited to share our latest success in percutaneous Radiofrequency Ablation (RFA) treatments using the Curaway Multichannel RF generator and our Fixed Internally Cooled Electrodes. By employing two or three electrodes simultaneously under CT guidance, we've achieved: ✅ Larger Ablation Volumes: Our multi-electrode approach significantly enhances the ablation area, ensuring comprehensive treatment of the target tissue. ✅ Increased Safety: Using internally cooled electrodes minimizes the risk of overheating surrounding tissues, providing a safer treatment option for patients. ✅ Time Efficiency: By reducing the number of ablation sessions needed, our method offers a more time-efficient procedure without compromising effectiveness. Our innovative technology demonstrates short-term therapeutic effectiveness, setting a new standard in RFA treatments. Interested in learning more about how our Curaway Multichannel RF generator and internally cooled electrodes can benefit your practice? Contact us for detailed information! #HealthcareInnovation #MedicalTechnology #RadiofrequencyAblation #Curaway #PatientCare #MedicalDevices

💓 Johnson & Johnson MedTech gets FDA approval for Varipulse platform to treat AFib The Varipulse Platform is a pulsed field ablation (PFA) system that comprises the Varipulse Catheter, Trupulse Generator, and CARTO 3 Mapping System. CARTO 3 is a 3D electro-anatomical cardiac mapping system that enhances mapping capabilities to simplify procedures, reduce procedure time, and improve outcomes. The FDA approval of the Varipulse platform is based on data from the admIRE study, a multi-centre, non-randomised clinical trial in 291 patients across 30 healthcare centres in the US. Read more online: https://lnkd.in/eqxNhsEV 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing